世界の栄養障害型表皮水疱症治療市場2020年ｰ2030年：治療タイプ別（抗生物質、コルチコステロイド、オピオイド鎮痛薬、抗けいれん薬、その他）、疾患タイプ別、流通チャネル別

• 英文タイトル：Dystrophic Epidermolysis Bullosa Treatment Market (Treatment Type: Antibiotics, Corticosteroids, Opioid Analgesics, Anticonvulsant, and Others; Disease Type: Dominant Dystrophic Epidermolysis Bullosa [DDEB] and Recessive Dystrophic Epidermolysis Bullosa [RDEB]; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

• レポートコード：MRC2103G129 • 出版社/出版日：Transparency Market Research / 2020年11月26日 • レポート形態：英文、PDF、168ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥857,660 (USD5,795)	▷ お問い合わせ
Site Licence	￥1,301,660 (USD8,795)	▷ お問い合わせ
Enterprisewide Licence	￥1,745,660 (USD11,795)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

Transparency Market Research社の本調査資料では、世界の栄養障害型表皮水疱症治療市場を広く調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、治療タイプ別（抗生物質、コルチコステロイド、オピオイド鎮痛薬、抗けいれん薬、その他）分析、疾患タイプ別分析、流通チャネル別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の構成でまとめております。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・栄養障害型表皮水疱症治療の世界市場規模：治療タイプ別（抗生物質、コルチコステロイド、オピオイド鎮痛薬、抗けいれん薬、その他） ・栄養障害型表皮水疱症治療の世界市場規模：疾患タイプ別 ・栄養障害型表皮水疱症治療の世界市場規模：流通チャネル別 ・栄養障害型表皮水疱症治療の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況

Dystrophic Epidermolysis Bullosa Treatment Market – Scope of the Report

TMR’s report on the global dystrophic epidermolysis bullosa treatment market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2030. The report provides revenue of the global dystrophic epidermolysis bullosa treatment market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global dystrophic epidermolysis bullosa treatment market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global dystrophic epidermolysis bullosa treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global dystrophic epidermolysis bullosa treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global dystrophic epidermolysis bullosa treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global dystrophic epidermolysis bullosa treatment market.

The report delves into the competition landscape of the global dystrophic epidermolysis bullosa treatment market. Key players operating in the global dystrophic epidermolysis bullosa treatment market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global dystrophic epidermolysis bullosa treatment market that have been profiled in this report.

Key Questions Answered in Dystrophic Epidermolysis Bullosa Treatment Market Report

What is the scope of growth of companies present in the global dystrophic epidermolysis bullosa treatment market?
What will be the Y-o-Y growth of the global dystrophic epidermolysis bullosa treatment market between 2020 and 2030?
What is the influence of changing trends in technologies on the global dystrophic epidermolysis bullosa treatment market?
Will North America continue to be the most profitable market for dystrophic epidermolysis bullosa treatment providers?
Which factors are anticipated to hamper the growth of the global dystrophic epidermolysis bullosa treatment market during the forecast period?
Which are the leading companies in the global dystrophic epidermolysis bullosa treatment market?
Research Methodology

A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global dystrophic epidermolysis bullosa treatment market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global dystrophic epidermolysis bullosa treatment market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the dystrophic epidermolysis bullosa treatment market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the dystrophic epidermolysis bullosa treatment market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global dystrophic epidermolysis bullosa treatment market with accuracy. The study also uses the top-down approach to assess the revenues for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global dystrophic epidermolysis bullosa treatment market more reliably and accurately.

レポート目次

---

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Dystrophic Epidermolysis Bullosa Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Dystrophic Epidermolysis Bullosa Treatment Market Introduction
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, 2018–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Novel Therapies for Dystrophic Epidermolysis Bullosa Treatment
5.2. Pipeline Analysis
5.3. Potential Market of Phase 3 Pipeline Drug Therapies for Dystrophic Epidermolysis Bullosa
5.4. Epidemiology of Dystrophic Epidermolysis Bullosa
5.5. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)
5.6. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment Type, 2018–2030
6.3.1. Antibiotics
6.3.2. Corticosteroids
6.3.3. Opioid Analgesics
6.3.4. Anticonvulsant
6.3.5. Others
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Disease Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Disease Type, 2018–2030
7.3.1. Dominant Dystrophic Epidermolysis Bullosa
7.3.2. Recessive Dystrophic Epidermolysis Bullosa
7.4. Market Attractiveness Analysis, by Disease Type
8. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2018–2030
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Others
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Country/Region
10. North America Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2018–2030
10.2.1. Antibiotics
10.2.2. Corticosteroids
10.2.3. Opioid Analgesics
10.2.4. Anticonvulsant
10.2.5. Others
10.3. Market Value Forecast, by Disease Type, 2018–2030
10.3.1. Dominant Dystrophic Epidermolysis Bullosa
10.3.2. Recessive Dystrophic Epidermolysis Bullosa
10.4. Market Value Forecast, by Distribution Channel, 2018–2030
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Others
10.5. Market Value Forecast, by Country, 2018–2030
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Treatment Type
10.6.2. By Disease Type
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Value Forecast, by Treatment Type, 2018–2030
11.2.1. Antibiotics
11.2.2. Corticosteroids
11.2.3. Opioid Analgesics
11.2.4. Anticonvulsant
11.2.5. Others
11.3.Market Value Forecast, by Disease Type, 2018–2030
11.3.1. Dominant Dystrophic Epidermolysis Bullosa
11.3.2. Recessive Dystrophic Epidermolysis Bullosa
11.4.Market Value Forecast, by Distribution Channel, 2018–2030
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Others
11.5.Market Value Forecast, by Country/Sub-region, 2018–2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6.Market Attractiveness Analysis
11.6.1. By Treatment Type
11.6.2. By Disease Type
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2.Market Value Forecast, by Treatment Type, 2018–2030
12.2.1. Antibiotics
12.2.2. Corticosteroids
12.2.3. Opioid Analgesics
12.2.4. Anticonvulsant
12.2.5. Others
12.3.Market Value Forecast, by Disease Type, 2018–2030
12.3.1. Dominant Dystrophic Epidermolysis Bullosa
12.3.2. Recessive Dystrophic Epidermolysis Bullosa
12.4.Market Value Forecast, by Distribution Channel, 2018–2030
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Others
12.5.Market Value Forecast, by Country/Sub-region, 2018–2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6.Market Attractiveness Analysis
12.6.1. By Treatment Type
12.6.2. By Disease Type
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2.Market Value Forecast, by Treatment Type, 2018–2030
13.2.1. Antibiotics
13.2.2. Corticosteroids
13.2.3. Opioid Analgesics
13.2.4. Anticonvulsant
13.2.5. Others
13.3.Market Value Forecast, by Disease Type, 2018–2030
13.3.1. Dominant Dystrophic Epidermolysis Bullosa
13.3.2. Recessive Dystrophic Epidermolysis Bullosa
13.4.Market Value Forecast, by Distribution Channel, 2018–2030
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Others
13.5.Market Value Forecast, by Country/Sub-region, 2018–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6.Market Attractiveness Analysis
13.6.1. By Treatment Type
13.6.2. By Disease Type
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Analysis and Forecast
14.1.Introduction
14.1.1. Key Findings
14.2.Market Value Forecast, by Treatment Type, 2018–2030
14.2.1. Antibiotics
14.2.2. Corticosteroids
14.2.3. Opioid Analgesics
14.2.4. Anticonvulsant
14.2.5. Others
14.3.Market Value Forecast, by Disease Type, 2018–2030
14.3.1. Dominant Dystrophic Epidermolysis Bullosa
14.3.2. Recessive Dystrophic Epidermolysis Bullosa
14.4.Market Value Forecast, by Distribution Channel, 2018–2030
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Others
14.5.Market Value Forecast, by Country/Sub-region, 2018–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6.Market Attractiveness Analysis
14.6.1. By Treatment Type
14.6.2. By Disease Type
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competitive Landscape
15.1. Company Profiles
15.1.1. Krystal Biotech
15.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.1.2. Growth Strategies
15.1.1.3. SWOT Analysis
15.1.2. Castle Creek Biosciences, Inc.
15.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.2.2. Growth Strategies
15.1.2.3. SWOT Analysis
15.1.3. Abeona Therapeutics, Inc.
15.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.3.2. Growth Strategies
15.1.3.3. SWOT Analysis
15.1.4. Amryt Pharma plc
15.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.4.2. Growth Strategies
15.1.4.3. SWOT Analysis
15.1.5. Wings Therapeutics
15.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.5.2. Growth Strategies
15.1.5.3. SWOT Analysis
15.1.6. Phoenix Tissue Repair
15.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.6.2. Growth Strategies
15.1.6.3. SWOT Analysis
15.1.7. InMed Pharmaceuticals, Inc.
15.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.7.2. Growth Strategies
15.1.7.3. SWOT Analysis
15.1.8. RegeneRx
15.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.8.2. Growth Strategies
15.1.8.3. SWOT Analysis
15.1.9. Holostem Terapie Avanzate S.r.l.
15.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.9.2. Growth Strategies
15.1.9.3. SWOT Analysis

List of Tables

Table 01: Global Dystrophic Epidermolysis Bullosa Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2030

Table 02: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 03: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 04: Global Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 05: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 06: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 07: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 08: North America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 09: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 10: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 11: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 12: Europe Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel ,2018–2030

Table 13: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 14: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 15: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 16: Asia Pacific Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 17: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 18: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 19: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 20: Latin America Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel ,2018–2030

Table 21: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 22: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Product, 2018–2030

Table 23: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 24: Middle East & Africa Dystrophic Epidermolysis Bullosa Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

---